Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer

✍ Scribed by Klaus Jung; Lars Nowak; Michael Lein; Friedrich Priem; Dietmar Schnorr; Stefan A. Loening

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: French
• Weight: 74 KB
• Volume: 74
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/(sici)1097-0215(19970422)74:2<220::aid-ijc14>3.0.co;2-h

✦ Synopsis

We analyzed blood plasma concentrations of matrix metalloproteinase-1 and -3 (MMP-1; MMP-3), the tissue inhibitor of metalloproteinase-1 (TIMP-1) and the complex MMP-1/ TIMP-1, and looked for any correlation with prostate cancer stage. These components were measured by ELISA tests specific for these proteins in healthy male controls (n 5 35), and in patients with benign prostatic hyperplasia (BPH; n 5 29), with prostate cancer (PCa) without metastasis (T2,3pN0M0; n 5 29) and with PCa with metastatic disease (T2,3,4pN1,2M1; n 5 18). Mean values of MMP-1 and of the complex MMP-1/TIMP-1 were not different among the 4 groups studied. The mean MMP-3 and especially TIMP-1 concentrations were significantly higher in PCa patients with metastases compared with controls, BPH and PCa patients without metastases. Ten of these 18 patients had TIMP-1 concentrations higher than the upper reference limit. TIMP-1 concentrations were correlated with staging but not with grading. Our results point towards plasma TIMP-1 concentration as a potential marker of malignant progression of PCa.